TEL AVIV, Israel, Oct. 31, 2017 /PRNewswire/ -- Cellect
Biotechnology Ltd. (Nasdaq: APOP),a developer of stem cell
selection technology, announced today that Company CEO, Dr.
Shai Yarkoni, was chosen to present
Cellect technology and recent advancements at the Bio-Europe 2017
conference in Berlin
(https://ebdgroup.knect365.com/bioeurope/about-bio-europe)
alongside other selected industry leaders including Andrew Yost, VP, Corporate Development,
REGENXBIO Inc., Gabriele Proetzel,
Director, Regenerative Medicine, Takeda and
Sharon Brownlow, Head of Collaborations - Manufacturing
Centre, The Cell and Gene Therapy Catapult. The panel will be
moderated by the Founder of Alliance of Regenerative Medicine
(ARM).
The 23rd annual BIO-Europe is Europe's largest partnering conference serving
the global biotechnology industry. Delegates from all parts of the
biotechnology value chain come to BIO-Europe with the aim to
identify, engage and enter into strategic relationships.
Dr. Shai Yarkoni, Company CEO has
commented: "Cellect is emerging as a significant player and front
runner in the stem cell industry. We aim to enter into strategic
alliances with bio / pharma leaders to drive ApoGraft™ adoption
worldwide. We are gaining significant global recognition and are
expanding our activities to engage with as many enterprises as
possible towards the commercialization of our technology.
Bio-Europe is a fantastic opportunity for forming such
collaborations on a global scale with the top industry companies of
our field."
BIO-Europe partnering event draws over 3,800 industry attendees
from over 60 countries, representing more than 2,000 companies for
three days of high level networking offering high level workshops,
panels and company presentations of top selected companies.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: "APOP", "APOPW") has developed a
breakthrough technology for the selection of stem cells from any
given tissue that aims to improve a variety of stem cell
applications.
The Company's technology is expected to provide pharma
companies, medical research centers and hospitals with the tools to
rapidly isolate stem cells in quantity and quality that will allow
stem cell related treatments and procedures. Cellect's technology
is applicable to a wide variety of stem cell related treatments in
regenerative medicine and that current clinical trials are aimed at
the cancer treatment of bone marrow transplantations.
Forward Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. For
example, forward-looking statements are used in this press release
when we discuss our plans to enter into strategic alliances. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. In addition, historical results or
conclusions from scientific research and clinical studies do not
guarantee that future results would suggest similar conclusions or
that historical results referred to herein would be interpreted
similarly in light of additional research or otherwise. The
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; we may
encounter delays or obstacles in launching and/or successfully
completing our clinical trials; our products may not be approved by
regulatory agencies, our technology may not be validated as we
progress further and our methods may not be accepted by the
scientific community; we may be unable to retain or attract key
employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our
process; our products may wind up being more expensive than we
anticipate; results in the laboratory may not translate to equally
good results in real clinical settings; results of preclinical
studies may not correlate with the results of human clinical
trials; our patents may not be sufficient; our products may harm
recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications, which could
cause the actual results or performance of the Company to differ
materially from those contemplated in such forward-looking
statements. Any forward-looking statement in this press release
speaks only as of the date of this press release. The Company
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual
Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities
and Exchange Commission, or SEC, which is available on the SEC's
website, www.sec.gov. and in the Company's period filings with the
SEC and the Tel-Aviv Stock Exchange.
Contact
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial
Officer
www.cellect.co
+972-9-974-1444
View original
content:http://www.prnewswire.com/news-releases/cellect-chosen-among-selected-global-leaders-presenting-at-bio-europe-2017-conference-addressing-over-3800-industry-specialists-from-over-2000-world-leading-companies-300546342.html
SOURCE Cellect Biotechnology Ltd.